Neurocognitive Assessment and Rehabilitation Market Size, Share and Trends Analysis, By Component (Hardware, Services and Solutions), By Therapy (CBT, Speech & Language Therapy, Computer-Assisted Cognitive Rehabilitation, Virtual Reality–Based Therapy and Others), By Application, By End-Use, and By Region, Forecast 2026-2033

Neurocognitive Assessment and Rehabilitation Market Overview and Key Insights:

Neurocognitive assessment and rehabilitation market size reached USD 14.52 Billion in 2025 and is expected to register a revenue CAGR of 9.4% during the forecast period. Neuropsychological examinations are critical in designing successful rehabilitation regimens for patients with neurological disorders. These examinations provide critical insights into how brain function influences thinking, conduct, and emotional well-being. Neuropsychological examinations are typically part of a larger, multidisciplinary strategy that includes neuropsychologists, neurologists, physiotherapists, occupational therapists, speech and language therapists, and the patient’s family or caregivers.

Market Drivers:

Rising prevalence of neurological and cognitive disorders is a key driver driving the market revenue growth. According to the Alzheimer’s Association, Alzheimer’s disease affects more than 7 million Americans. By 2050, this figure is expected to increase to approximately 13 million. Alzheimer’s affects around one in every nine adults aged 65 and older. At the age of 45, women have a one-in-five lifetime risk of developing Alzheimer’s, while males have one in ten. Nearly 12 million Americans offer unpaid care to persons suffering from Alzheimer’s disease or other forms of dementia. Nearly three-fifths of Americans answered they would accept moderate or extremely high levels of risk in exchange for slowing the advancement of Alzheimer’s disease.

Early detection and therapy are crucial for treating Alzheimer’s disease. Cognitive training for Alzheimer’s is a promising therapy option for early-stage Alzheimer’s disease that can assist patients in maintaining and improving their cognitive abilities, managing the emotional and psychological effects of cognitive loss, and improving their overall quality of life. Combining cognitive rehabilitation with other treatments, like as medication and lifestyle changes, can help to manage symptoms and reduce the disease’s course.

On December 2025, Lumos Labs, the company behind the widely used Lumosity brain-training platform with over 100 million users, announced that its LumosityRx digital therapeutic has received FDA 510(k) clearance. LumosityRx is a prescription mobile app designed to enhance attention in adults aged 22–55 with ADHD, using clinically tested versions of 13 cognitive training games focused on key attention-related processes.

Market Opportunity:

Growing use in mental health, geriatric care, and preventive wellness programs acts as opportunities for neurocognitive assessment and rehabilitation market. According to the American Heart Association, about 800,000 people in the United States experience a stroke each year, and one-third of all adults have at least one enhanced risk factor for stroke, such as high blood pressure, high cholesterol, diabetes, obesity, or smoking. The development of effective treatments for long-term stroke-related impairments has been difficult, but recent research on the use of biomarkers to predict stroke recovery outcomes is promising. Biomarkers can enhance this precision by offering more detailed insights to help clinicians determine the most effective interventions from a wide range of rehabilitation options. Combining precision rehabilitation with medical approaches is an exciting prospect, as it has the potential to optimize function, reduce disability, and improve quality of life during stroke recovery.

On August 2024, Otsuka Precision Health, Inc. and Click Therapeutics, Inc. have announced the commercial launch of Rejoyn. Rejoyn was approved by the US Food and Drug Administration (FDA) in March 2024 as the first and only prescription digital therapy for the treatment of major depressive disorder (MDD) symptoms. Rejoyn incorporates cognitive emotional brain training exercises such as the Emotional Faces Memory Task (EFMT), which tap into the brain’s innate potential to adapt, commonly known as neuroplasticity, as well as short skills-based therapy courses based on Cognitive Behavioral Therapy.

Recent Trends:

Emerging trends include Artificial Intelligence (AI)-enabled cognitive analytics, VR/AR-based rehabilitation, gamified cognitive therapy, cloud-based and remote neurorehabilitation platforms, and Brain Computer Interfaces (BCI).

Cognitive AI simulates human brain and cognition using machine learning, deep learning, and artificial neural networks. Cognitive computing systems replicate human thought processes by using machine learning, deep learning, and artificial neural networks to make human-like decisions and solve problems. These systems are powered by cognitive computing frameworks, which process large amounts of data to detect patterns and deliver insights that improve decision-making. In healthcare, these systems evaluate patient data and clinical records to offer appropriate therapies while assuring diagnosis accuracy.

Businesses use AI-powered chatbots and cognitive computing solutions to improve human-computer interactions by providing personalized, context-aware responses. These cognitive computing systems use natural language processing to anticipate client demands, providing personalized recommendations and seamless involvement.

On April 2025, BIOLAN and AITA MENNI aim to improve post-stroke neurorehabilitation procedures through AI integration. This cooperation intends to develop artificial intelligence models that combine physiological, clinical, and genetic data with neurorehabilitation findings, resulting in a system capable of tailoring therapies based on each patient’s evolution.

Restraints & Challenges:

Measurement scales and scoring systems for neurocognitive examinations, such as the Mini-Mental State Exam (MMSE) and the Montreal Cognitive Assessment (MoCA), provide only restricted measurements of neurocognitive ability. The most significant limitations of measurement scales and scoring systems for neurocognitive assessments are their narrowness and lack of ecological validity, as well as the concept of realism, which refers to how the design of neurocognitive evaluation matches and aligns with the neurocognitive states required to complete Activities of Daily Living (ADL).

Full neuropsychological examinations necessitate professional administration, lengthy wait periods, and multiple hours, making routine follow-up difficult and costly. Furthermore, the process can create distress for certain dementia patients. Patients in distant areas may not have access to specialists, making quick cognitive assessments difficult without digital technologies.

Component Segment Insights and Analysis:

Based on the component, neurocognitive assessment and rehabilitation market is segmented into hardware, solution, and services.

Hardware segment contributed the largest market share in 2025. It is further sub segmented into EEG systems, VR/AR headsets, neurofeedback devices, and wearable cognitive trackers. Equipment is essential in neurological rehabilitation since it speeds up and improves the recovery process. It enables therapists and patients to achieve specific treatment objectives, increase functional abilities, and encourage independence. The utilization of technology and novel equipment, such as virtual reality systems, robotic assisting devices, and electrical stimulation devices, has also emerged as a viable approach to neurological rehabilitation.

The use of computerized neuropsychological assessment devices (CNADs) is becoming increasingly popular in clinical practice, research, and clinical trials. CNADs range from stand-alone computer-administered versions of traditional examiner-administered tests to completely web-integrated testing stations for general or specific applications. This has been a highly busy research and development area, with fresh tests and discoveries issued on a continual basis.

On January 2025, Otsuka Pharmaceutical Co., Ltd., and Ai-BrainScience Inc. have announced that MIREVO, a software for neuropsychological testing to support medical treatment of dementia, is the first Software as a Medical Device (SaMD) in the field of dementia. MIREVO is a neuropsychological evaluation method that employs eye tracking technology. The test is simple to administer, and the results can be acquired in around three minutes using the MIREVO app on a tablet.

Therapy Segment Insights and Analysis:

Based on the therapy, neurocognitive assessment and rehabilitation market is segmented into Cognitive Behavioral Therapy (CBT), speech & language therapy, computer-assisted cognitive rehabilitation, virtual reality–based therapy, neurofeedback & brain stimulation therapy, and gamified cognitive training.

Cognitive Behavioral Therapy (CBT) segment contributed the largest market share in 2025. Cognitive behavior therapy (CBT) is an effective treatment method for a variety of mental and emotional health problems, including anxiety and depression. It is generally recognized that adults with ADHD are more likely than the general population to have co-occurring anxiety and depressive disorders. Treatments that include CBT for these diseases may be very beneficial to many individuals with ADHD, even if they are not particularly designed to address the symptoms and impairment associated with ADHD.

On October 2025, Neuro Wellness Spa, a leader in compassionate, evidence-based mental health, has announced the launch of their Teen Talk Therapy program, a specialized psychotherapy service for adolescents aged 12 to 17. The program provides both virtual sessions throughout California and in-person appointments at select Neuro Wellness Spa sites, such as Brea and Manhattan Beach. This program eliminates the need for long-term intense therapy in favor of a targeted, goal-oriented approach to treatment that is customized to the needs of today’s teenagers.

Application Segment Insights and Analysis:

Based on the application, neurocognitive assessment and rehabilitation market is segmented into dementia & Alzheimer’s disease, Stroke & Traumatic Brain Injury (TBI), Parkinson’s disease & multiple sclerosis, learning disabilities, mental health disorders, developmental disorders, and healthy aging & preventive brain health.

Stroke & traumatic brain injury segment contributed the largest market share in 2025. Each year, roughly 223,000 persons in the United States are hospitalized for traumatic brain injuries. TBIs account for around 70,000 deaths each year. According to the CDC, more than 55% of people who have had a moderate or severe brain damage are still unable to return to work two years later. Annually, around 2.5 million people suffer a traumatic brain injury, which can result in impairments and death. BTF works to reduce this number and improve the recovery process for these people by intervening early and using proven, evidence-based principles.

On December 2024, CLR Neurosthenics has released CLR Advantage, a ground-breaking solution that uses interactive software and a wearable, wireless sensor network to collect real-time neurophysiological data while athletes do pre-program physical exercises, cognitive tests, reaction games, and position drills. The system then uses NASA technology to evaluate biometric signals and generate reports on neurophysiological capacities such as brain connectivity, power, activation, and symmetry while performing various physical and mental exercises.

Geographical Outlook:

Neurocognitive assessment and rehabilitation market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Neurocognitive Assessment and Rehabilitation Market:

North America is registered to have highest market share in neurocognitive assessment and rehabilitation market in 2025. This is mainly driven by rising prevalence of neurological and cognitive disorders and advancements in Digital Therapeutics (DTx) and AI-based cognitive assessment tools. According to the Parkinson Foundation, in the United States, an estimated 1.1 million people live with Parkinson’s disease (PD). This figure is predicted to increase to 1.2 million by 2030. Parkinson’s is the second most common neurological illness after Alzheimer’s. Every year, around 90,000 people in the United States are diagnosed with Parkinson’s disease. It is believed that around ten million people worldwide suffer with Parkinson’s disease. Men are 1.5 times more likely to develop Parkinson’s disease than women.

On December 2025, QHSLab Inc. has announced the release of Q-Cog, a comprehensive cloud-based cognitive assessment designed to assist primary care providers in identifying Mild Cognitive Impairment (MCI) and dementia-related risks earlier in the disease process. Q-Cog integrates established cognitive, behavioral, and functional screening into a unified digital workflow, allowing clinicians to meet CMS screening criteria while also facilitating risk adjustment and payment under neurocognitive and behavioral health codes.

Asia Pacific Neurocognitive Assessment and Rehabilitation Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, driven by the rising prevalence of neurological and mental health problems like dementia, Alzheimer’s, and depression. Demand for improved cognitive evaluation tools is increasing as people become more aware of the need of early diagnosis and intervention. Technological breakthroughs, such as AI and digital platforms, improve the accuracy and usability of cognitive training solutions. Around 8.8 million Indians over the age of 60 suffer from dementia, accounting for 7.4% of the country’s elderly population.

This figure is likely to climb as India ages; by 2050, one in every five Indians would be a senior citizen, with the total number of elderly Indians reaching 340 million. Using population predictions and data from the Longitudinal Aging Study in India (LASI), researchers predict that India’s dementia prevalence among the elderly would double from 8.8 million in 2016 to 16.9 million in 2036.

On April 2025, Ivory, an early-stage brain health firm, announced the successful completion of its most recent USD 1 million investment round. The round was co-led by IIM-A Ventures, IIM Ahmedabad’s entrepreneurship centre, and Capital-A, which previously sponsored Ivory at the pre-seed stage. Its goal is to enable early diagnosis of cognitive decline via neuroscience-based digital tests, allowing individuals to act before symptoms worsen. 1Crowd and Stanford Angels contributed additional funds to the round.

Competition Analysis:

Neurocognitive assessment and rehabilitation market is characterized by a fragmented structure, with several players competing across various segments and regions. List of major players included in neurocognitive assessment and rehabilitation market report are:

• Cogstate Ltd.
• BrainCheck, Inc.
• Cambridge Cognition Ltd
• SCHUHFRIED
• CNS Vital Signs, LLC
• Lumos Labs
• MindMaze group 
• Constant Therapy Health
• Neurotrack Technologies, Inc.
• Signant Health
• NeuronUP, S.L.
• MoCA Test Inc.
• Linus Health
• Viewmind
• NeuroCatch Inc.

Strategic Developments in Neurocognitive Assessment and Rehabilitation Market:

• In January 2025, Cambridge Cognition Holdings plc, a brain health software company that develops digital technologies to promote brain health research and therapy, has announced the debut of its in-house Rater Training program. Adding in-house Rater Training to the Group’s electronic Clinical Outcome Assessments (eCOA) and Automated Quality Assurance technologies would allow the Company to become a single platform provider while also expanding the size of the accessible CNS clinical trials market in which its solutions may be used.
• In March 2024, BrainCheck, Inc., a digital health developer that brings first-of-its-kind technology to the booming digital cognitive testing market, has announced a USD 15 million new funding round. The capital will help BrainCheck gain commercial traction, develop innovation in its product line, build on existing clinical data, and broaden the company’s impact throughout the healthcare landscape, including substantial integrations with healthcare systems. This announcement follows the recent debut of BrainCheck’s next-generation platform and 3-minute screening solution, which allows clinicians to evaluate and monitor patients’ cognitive ability at any time and from any location.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2023 to 2024, with 2025 serving as the base year for market size calculations. The forecast period extends from 2026 to 2033.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of Neurocognitive Assessment and Rehabilitation Market Report:

Neurocognitive Assessment and Rehabilitation market report offers a detailed analysis of market size, including historical revenue (in USD Billion) data for 2023-2024 and revenue forecasts for 2026-2033 across the following segments:

• Component Outlook (Revenue, USD Billion; 2023-2033)
  • Hardware
    • EEG systems
    • VR/AR headsets
    • Neurofeedback devices
    • Wearable cognitive trackers
  • Services
    • Emergency Mental Health Services
    • Outpatient Counselling
    • Home-based Treatment Services
    • Inpatient Hospital Treatment Services
    • Training & Support
    • Consulting
  • Solution
    • Assessment
      • Biometrics Assessment
      • Pen & Paper-based Assessment
      • Hosted Assessment
    • Data Analysis & Reporting
    • Data Management
    • Others

• Therapy Outlook (Revenue, USD Billion; 2023-2033)
  • Cognitive Behavioral Therapy (CBT)
  • Speech & Language Therapy
  • Computer-Assisted Cognitive Rehabilitation
  • Virtual Reality–Based Therapy
  • Neurofeedback & Brain Stimulation Therapy
  • Gamified Cognitive Training

• Application Outlook (Revenue, USD Billion; 2023-2033)
  • Dementia & Alzheimer’s Disease
  • Stroke & Traumatic Brain Injury (TBI)
  • Parkinson’s Disease & Multiple Sclerosis
  • Learning Disabilities
  • Mental Health Disorders
  • Developmental Disorders
  • Healthy Aging & Preventive Brain Health

• End-Use Outlook (Revenue, USD Billion; 2023-2033)
  • Hospitals & Rehabilitation Centers
  • Mental Health Clinics
  • Academic & Research Institutions
  • Home Healthcare and Remote Users
  • Corporate Wellness Programs
  • Military & Veteran Healthcare Systems

• Regional Outlook (Revenue, USD Billion; 2023-2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about Neurocognitive Assessment and Rehabilitation market report